Non-Dilutive Investment and Product License includes licensing fee and development costs
EastGate to receive the first non-dilutive investment tranch from the total funding up to $5 million USD as per the terms of the Definitive Agreement.
Genome Pharma is the parent company of Netris/Origin BioPharmaceuticals the company's Joint Venture Partner
Terms of the Agreement reflects long term vision and supports company's business plan
Drug Development and Nutraceuticals Covered in JV.
EastGate to receive funding in tranches up to $5 million USD.
The Share Reserve with Transfer Agent has been cancelled and all remaining shares have been returned to EastGate Biotech.
The Kell Group Limited served as an agent for related-party advances.